{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:03:41Z","timestamp":1779750221910,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":184,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["531002021"],"award-info":[{"award-number":["531002021"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["531002021"],"award-info":[{"award-number":["531002021"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["531002021"],"award-info":[{"award-number":["531002021"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of vaginal self-sampling for cervical cancer screening is promising and increasing. However, triage cytology cannot be performed on vaginal self-sampling material after a high-risk human papilloma virus (hrHPV)-positive result. In our recent discovery study, we identified a three-marker panel with high sensitivity (82%) and specificity (74%) for CIN3 or worse (CIN3+). In the present study, we performed the clinical validation of this three-marker panel using real-world hrHPV-positive vaginal self-samples obtained through the Dutch screening programme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The markers\n                      <jats:italic>LHX8<\/jats:italic>\n                      ,\n                      <jats:italic>EPB41L3<\/jats:italic>\n                      and\n                      <jats:italic>ANKRD18CP<\/jats:italic>\n                      were analysed using quantitative methylation-specific PCR (QMSP) on a consecutive cohort of hrHPV-positive vaginal self-samples (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092482: 408 CIN3+\u2009and 2074\u2009&lt;CIN3). Diagnostic performance was assessed using sensitivity and specificity derived from receiver operating characteristics (ROC) analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The three-marker panel showed 73% (298\/408) sensitivity and 79% (1640\/2071) specificity to detect CIN3+, and identified 96% (21\/22) of cervical cancer cases. A scenario analysis was performed on a virtual population of 100 000 hrHPV-positive women using vaginal self-sampling, comparing our methylation triage test with current cytology triage testing. This analysis revealed that more cancers (864 vs. 684 or 770 for 80 or 90% uptake) would be detected with our methylation panel, while referral rates (29% vs. 31% for both 80 and 90% uptake) and detection of CIN3 (72% vs. 68 or 77% for 80 or 90% uptake) would be similar for methylation and cytology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared to cytology triage testing, DNA methylation triage analysis using our three-marker panel offers an appropriate alternative to detect CIN3+\u2009in hrHPV-positive vaginal self-samples. Implementation of the DNA methylation triage test would not only increase cancer detection, but would also eliminate the need for physician visits for cytological triage testing. In addition, it would accelerate referral decisions, ultimately reducing uncertainty and ensuring timely screening completion for all women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-025-02020-w","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T03:03:23Z","timestamp":1763867003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical validation of a three-marker methylation panel to detect CIN3+\u2009in vaginal self-samples in the Dutch population-based screening programme"],"prefix":"10.1186","volume":"18","author":[{"given":"Jolien","family":"de Waard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkajyoti","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine T.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettien M.","family":"van Hemel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha D.","family":"Esajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin M.","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Bea A.","family":"Wisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"key":"2020_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2020_CR2","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ejca.2009.07.018","volume":"45","author":"M Arbyn","year":"2009","unstructured":"Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member States of the European union. Eur J Cancer. 2009;45:2640\u20138.","journal-title":"Eur J Cancer"},{"key":"2020_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(04)16674-9","volume":"364","author":"PJ Peto","year":"2004","unstructured":"Peto PJ, Gilham PC, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364:249\u201356.","journal-title":"Lancet"},{"key":"2020_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ijc.21955","volume":"119","author":"J Cuzick","year":"2006","unstructured":"Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095\u2013101.","journal-title":"Int J Cancer"},{"key":"2020_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/jnci\/djq562","volume":"103","author":"M Schiffman","year":"2011","unstructured":"Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368\u201383.","journal-title":"J Natl Cancer Inst"},{"key":"2020_CR6","unstructured":"RIVM. Zelfafnameset. 2019. Available from: https:\/\/www.rivm.nl\/bevolkingsonderzoek-baarmoederhalskanker\/zelfafnameset"},{"key":"2020_CR7","unstructured":"RIVM. Bredere inzet zelfafnameset. 2023. Available from: https:\/\/www.rivm.nl\/bevolkingsonderzoek-baarmoederhalskanker\/professionals\/actuele-ontwikkelingen. 2023."},{"key":"2020_CR8","unstructured":"Erasmus MC - PALGA. Bevolkingsonderzoek Baarmoederhalskanker Monitor 2017. 2018. Available from: https:\/\/www.rivm.nl\/sites\/default\/files\/2019-06\/LEBAmon2017-def-190626.pdf"},{"key":"2020_CR9","unstructured":"Erasmus MC. Monitor bevolkingsonderzoek Baarmoederhalskanker 2023. 2024. Available from: https:\/\/www.rivm.nl\/sites\/default\/files\/2024-11\/Monitor-BVO-BMHK-2023.pdf"},{"key":"2020_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40271-021-00550-y","volume":"15","author":"M Dieleman","year":"2022","unstructured":"Dieleman M, De Waard J, Wisman GBA, Schuuring E, Esajas MD, Vermeulen KM, et al. Preferences and experiences regarding the use of the Self-Sampling device in HrHPV screening for cervical cancer. Patient - Patient-Centered Outcomes Res. 2022;15:245\u201353.","journal-title":"Patient - Patient-Centered Outcomes Res"},{"key":"2020_CR11","unstructured":"Integraal Kankercentrum Nederland. Monitor bevolkingsonderzoek baarmoederhalskanker 2021. 2022. Available from: https:\/\/www.rivm.nl\/documenten\/monitor-bevolkingsonderzoek-baarmoederhalskanker-2021"},{"key":"2020_CR12","unstructured":"Erasmus MC. Monitor bevolkingsonderzoek Baarmoederhalskanker 2022. 2023. Available from: https:\/\/www.rivm.nl\/sites\/default\/files\/2023-10\/Monitor-BVO-Baarmoederhalskanker-2022.pdf"},{"key":"2020_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1586\/14737159.2014.897610","volume":"14","author":"AT Lorincz","year":"2014","unstructured":"Lorincz AT. Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Rev Mol Diagn. 2014;14:293\u2013305.","journal-title":"Expert Rev Mol Diagn"},{"key":"2020_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2050","volume":"7","author":"CBJ Woodman","year":"2007","unstructured":"Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7:11\u201322.","journal-title":"Nat Rev Cancer"},{"key":"2020_CR15","first-page":"131","volume":"32","author":"N Yang","year":"2010","unstructured":"Yang N, Nijhuis ER, Volders HH, Eijsink JJH, Lendvai \u00c1, Zhang B, et al. Gene promoter methylation patterns throughout the process of cervical carcinogenesis. Cell Oncol. 2010;32:131\u201343.","journal-title":"Cell Oncol"},{"key":"2020_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-016-0196-3","volume":"8","author":"A Boers","year":"2016","unstructured":"Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, et al. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2\/3. Clin Epigenetics. 2016;8:1\u201316.","journal-title":"Clin Epigenetics"},{"key":"2020_CR17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/ijc.31897","volume":"144","author":"RW van Leeuwen","year":"2019","unstructured":"van Leeuwen RW, O\u0161trbenk A, Poljak M, van der Zee AGJ, Schuuring E, Wisman GBA. DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort. Int J Cancer. 2019;144:746\u201354.","journal-title":"Int J Cancer"},{"key":"2020_CR18","first-page":"1251","volume":"146","author":"LMA De Strooper","year":"2014","unstructured":"De Strooper LMA, Meijer CJLM, Berkhof J, Hesselink AT, Snijders PJF, Steenbergen RDM, et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2\/3 lesions. Chest. 2014;146:1251\u20137.","journal-title":"Chest"},{"key":"2020_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13148-017-0419-2","volume":"9","author":"M Schmitz","year":"2017","unstructured":"Schmitz M, Wunsch K, Hoyer H, Scheungraber C, Runnebaum IB, Hansel A, et al. Performance of a methylation specific real-time PCR assay as a triage test for HPV-positive women. Clin Epigenetics. 2017;9:118.","journal-title":"Clin Epigenetics"},{"key":"2020_CR20","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.2147\/CMAR.S246103","volume":"12","author":"L Zhang","year":"2020","unstructured":"Zhang L, Yu J, Huang W, Zhang H, Xu J, Cai H. A sensitive and simplified classifier of cervical lesions based on a methylation-specific PCR assay: a Chinese cohort study. Cancer Manag Res. 2020;12:2567\u201376.","journal-title":"Cancer Manag Res"},{"key":"2020_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2217\/epi-2019-0331","volume":"12","author":"S Dick","year":"2020","unstructured":"Dick S, Verhoef L, De Strooper LMA, Cioc\u0103nea-Teodorescu I, Wisman GBA, Meijer CJLM, et al. Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. Epigenomics. 2020;12:1569\u201378.","journal-title":"Epigenomics"},{"key":"2020_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13148-023-01517-6","volume":"15","author":"J de Waard","year":"2023","unstructured":"de Waard J, Bhattacharya A, de Boer MT, van Hemel BM, Esajas MD, Vermeulen KM, et al. Identification of a methylation panel as an alternative triage to detect CIN3\u2009+\u2009in hrHPV-positive self-samples from the population-based cervical cancer screening programme. Clin Epigenetics. 2023;15:103.","journal-title":"Clin Epigenetics"},{"key":"2020_CR23","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/bjc.2014.392","volume":"111","author":"A Boers","year":"2014","unstructured":"Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA, Massuger LF, et al. DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. Br J Cancer. 2014;111:1095\u2013101.","journal-title":"Br J Cancer"},{"key":"2020_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12885-015-1411-x","volume":"15","author":"CC Chang","year":"2015","unstructured":"Chang CC, Huang RL, Liao YP, Su PH, Hsu YW, Wang HC et al. Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm. BMC Cancer. 2015;15:418.","journal-title":"BMC Cancer"},{"key":"2020_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/bjc.2016.200","volume":"115","author":"R Luttmer","year":"2016","unstructured":"Luttmer R, De Strooper LMA, Dijkstra MG, Berkhof J, Snijders PJF, Steenbergen RDM, et al. FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. Br J Cancer. 2016;115:579\u201387.","journal-title":"Br J Cancer"},{"key":"2020_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Lang AG, Buchner A. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149\u201360.","journal-title":"Behav Res Methods"},{"key":"2020_CR27","doi-asserted-by":"publisher","first-page":"100235","DOI":"10.1016\/j.lanepe.2021.100235","volume":"11","author":"F Inturrisi","year":"2021","unstructured":"Inturrisi F, Aitken CA, Melchers WJG, van den Brule AJC, Molijn A, Hinrichs JWJ et al. Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the netherlands: an observational study. Lancet Reg Health - Europe. 2021;11:100235.","journal-title":"Lancet Reg Health - Europe"},{"key":"2020_CR28","unstructured":"Integraal Kankercentrum Nederland. Monitor bevolkingsonderzoek baarmoederhalskanker 2018. 2019. Available from: https:\/\/www.rivm.nl\/documenten\/monitor-bevolkingsonderzoek-baarmoederhalskanker-2018"},{"key":"2020_CR29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/15592294.2021.1992911","volume":"17","author":"L Verhoef","year":"2022","unstructured":"Verhoef L, Floore AN, Doorn S, Cuschieri K, Bhatia R, Hesselink AT, et al. Direct bisulphite conversion of cervical samples for DNA methylation analysis. Epigenetics. 2022;17:1173\u20139.","journal-title":"Epigenetics"},{"key":"2020_CR30","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/1055-9965.EPI-24-0046","volume":"33","author":"KR Kroon","year":"2024","unstructured":"Kroon KR, Bogaards JA, Heideman DA, Meijer CJ, Berkhof J. Colposcopy referral and CIN3\u2009+\u2009risk of human papillomavirus genotyping strategies in 1 cervical cancer screening 2 running title: HPV genotyping strategies for colposcopy referral 3. Cancer Epidemiol Biomark Prev. 2024;33:1037\u201345.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2020_CR31","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1016\/j.ejca.2009.07.022","volume":"45","author":"G Ronco","year":"2009","unstructured":"Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, et al. Process performance of cervical screening programmes in Europe. Eur J Cancer. 2009;45:2659\u201370.","journal-title":"Eur J Cancer"},{"key":"2020_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41416-023-02277-z","volume":"129","author":"L Verhoef","year":"2023","unstructured":"Verhoef L, Bleeker MCG, Polman N, Steenbergen RDM, Ebisch RMF, Melchers WJG, et al. Evaluation of DNA methylation biomarkers ASCL1 and LHX8 on HPV-positive self-collected samples from primary HPV-based screening. Br J Cancer. 2023;129:104\u201311.","journal-title":"Br J Cancer"},{"key":"2020_CR33","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41591-024-03014-6","volume":"30","author":"L Schreiberhuber","year":"2024","unstructured":"Schreiberhuber L, Barrett JE, Wang J, Redl E, Herzog C, Vavourakis CD, et al. Cervical cancer screening using DNA methylation triage in a real-world population. Nat Med. 2024;30:2251\u20137.","journal-title":"Nat Med"},{"key":"2020_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13148-020-00963-w","volume":"12","author":"C Dippmann","year":"2020","unstructured":"Dippmann C, Schmitz M, Wunsch K, Sch\u00fctze S, Beer K, Greinke C et al. Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays. Clin Epigenetics 2020;12;171.","journal-title":"Clin Epigenetics"},{"key":"2020_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ijc.33320","volume":"148","author":"J Bonde","year":"2021","unstructured":"Bonde J, Floore A, Ejegod D, Vink FJ, Hesselink A, van de Ven PM, et al. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: a large European multicenter study. Int J Cancer. 2021;148:396\u2013405.","journal-title":"Int J Cancer"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-02020-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-02020-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-02020-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T22:42:11Z","timestamp":1779748931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-025-02020-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2020"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-02020-w","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Local biobank permission was obtained according to the local and National Institute for Health and the Environment (RIVM) regulations to collect samples obtained within the PBS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the manuscript and consent to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ES and GBAW are inventors on patents related to the content of the manuscript. ES is a member of the scientific advisory board of Roche, Hologic Inc, QCMD and CC Diagnostics; received grants from CC Diagnostics and Abbott Molecular Inc.; and received travel reimbursements from Roche, Abbott Molecular Inc., Hologic Inc., and QCMD (all honoraria paid to UMCG account). GBAW is a member of the scientific advisory board of CC Diagnostics and Novosanis; and received grants from CC Diagnostics and Abbott Molecular Inc. (all honoraria paid to UMCG account). The other authors have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}